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1INTRODUCTION  
Recently a Kenyan High court in P.A.O 
and others v Attorney General and 
another1 (hereinafter P.A.O) handed 
down a judgment in relation to sections 
2, 32, and 34 of the Anti-Counterfeit Act2  
vis-à-vis Kenya’s obligations under 
international human rights law and the 
Constitution. For many Africans, access 
to medicines has remained a great 
challenge not least because of high 
prices mainly due to patent on these 
medicines. Although recent 
                                                 
1 PA.O and others v Attorney General and another 
High Court of Kenya at Nairobi Petition No. 
409 of 2009, (Judgment 2012). 
2 Anti-Counterfeit Act 13 of 2008. 
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developments across Africa had shown that modest progress has been made in realizing 
access to medicines for people living with HIV, a great percentage of those in need of 
these medicines are not receiving them. One of the major obstacles to access to 
medicines in Africa is patent rights enjoyed by pharmaceutical companies on essential 
medicines such as anti-retroviral drugs.  
It must be recalled that during the Doha Declaration on intellectual property and 
public health,3 members of the World Trade Organization (WTO) agreed that countries 
could invoke the flexibilities contained in the Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) Agreement to facilitate access to life-saving medications for 
their people. Sadly however, the victory at Doha by activists is being undermined by the 
activities of pharmaceutical companies and some developed countries, who have not 
only continued to oppose the use of TRIPS flexibilities, but have also pressurised 
developing countries to adopt TRIPS-plus intellectual property regime. This situation is 
not only at variance with the spirit of Doha but also raises the question of states’ duties 
to protect and promote the rights to health and life of their people. 
Against this backdrop this paper examines the decision of the Kenyan High Court 
in PA.O and others v Attorney General and another in relation to the nature of states’ 
obligations to ensure access to medicines for their people. First, the paper discusses the 
facts of this case and the decision reached by the court. It then critically evaluates the 
decision based on three important issues - access to medicines as a human right, patent 
versus human rights and the nature of state’s obligations in relation to access to 
medicines. The paper concludes by pointing out lessons African government should 
learn from this case.  
1.1 Facts of the case  
The petitioners in this case were all HIV positive adults, who had been living with HIV 
for periods ranging between eight and 19 years, who, with the exception of the second 
petitioner, had been on generic anti-retroviral drugs (ARVs) for about ten years.  The 
first petitioner claims that she received her medication free of charge from Medicines 
Sans Frontieres (MSF) which operated a treatment programme in conjunction with the 
government of Kenya.  The second petitioner, though HIV positive, not  on ARV,  but had 
a five-year old son who was HIV positive and on first line ARV, which he received free of 
charge from the MSF programme. . The third petitionerhad been living with HIV/AIDS 
for about eight years and received ARVs free of charge from MSF programme. All the 
petitioners were unemployed and could not personally afford to pay for their ARVs. 
                                                 
3 World Trade Organization, Doha Ministerial Declaration on the TRIPS Agreement and Public Health, 
WTO Doc No WT/MIN(01)/DEC/2 (2001). This seven-paragraph Declaration contains a number of 
important statements including the clarification on the use of flexibilities such as compulsory licensing, 
parallel importation and others.   
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The petitioners submitted that they have continued to receive their drugs free of 
charge by virtue of the Industrial Property Act4  which permits the importation of 
generic drugs. All of them were on first line ARV treatment combination of Stavudine 
(3TC), Zinoduvine(AZT) and Nevaripine (NVP)-two tablets per day. They challenged the 
constitutionality of sections 2, 33, and 34 of the Anti-Counterfeit Act.5  The petitioners 
                                                 
4 Industrial Property Act 3 of 2001. 
5Anti-Counterfeit Act of 2008 Section 2. In this Act, unless the context otherwise requires— 
“Agency” means the Anti-Counterfeit Agency established under section 3; 
“Commissioner” shall have the meaning assigned to it under the Kenya Revenue Authority Act (Cap. 
469); 
“complainant” means a person, institution, government agency or state corporation entitled to lay a 
complaint under section 33 (1), or who has laid such a complaint; 
“counterfeiting” means taking the following actions without the authority of the owner of intellectual 
property right subsisting in Kenya or elsewhere in respect of protected goods— 
(a) the manufacture, production, packaging, re-packaging, labelling or making, whether in Kenya or 
elsewhere, of any goods whereby those protected goods are imitated in such manner and to such a 
degree that those other goods are identical or substantially similar copies of the protected goods; 
(b) the manufacture, production or making, whether in Kenya or elsewhere, the subject matter of 
that intellectual property, or a colourable imitation thereof so that the other goods are calculated to 
be confused with or to be taken as being the protected goods of the said owner or any goods 
manufactured, produced or made under his licence; 
(c) the manufacturing, producing or making of copies, in Kenya or elsewhere, in violation of an 
author’s rights or related rights; 
(d) in relation to medicine, the deliberate and fraudulent mislabelling of medicine with respect to 
identity or source, whether or not such products have correct ingredients, wrong ingredients, have 
sufficient active ingredients or have fake packaging; 
Section 33. (1) Any holder of an intellectual property right, his successor in title, licensee or agent 
may, in respect of any protected goods, where he has reasonable cause to suspect that an offence 
under section 32 has been or is being committed, or is likely to be committed, by any person, lay a 
complaint with the Executive Director. 
(2) The complainant shall furnish, to the satisfaction of the Executive Director, such information and 
particulars, as may be prescribed, to the effect that the goods with reference to which that offence has 
allegedly been, or is being, or is likely to be, committed, prima facie are counterfeit goods. 
(3) Where the Executive Director is reasonably satisfied– 
(a) that the complainant is a person entitled to lay a complaint under subsection (1); and 
(b) that— 
(i) the goods claimed to be protected goods, prima facie are protected goods; and 
(ii) the intellectual property right, the subject matter of which is alleged   to have been applied to 
the offending goods, prima facie subsists; and 
(c) that the suspicion on which the complaint is based appears to be reasonable in the 
circumstances, the Executive Director shall cause appropriate steps to be taken in accordance with 
section n 23 (1). 
(4) The preceding provisions of this section shall not preclude an inspector from taking any 
appropriate steps on his own initiative in relation to any act or conduct believed or suspected to be an 
act of dealing in counterfeit goods, provided the provisions of this Act are complied with. 
(5) Nothing in this section shall preclude the Executive Director from causing appropriate steps to be 
taken in accordance with section 23 (1) in the event of an infringement of an intellectual property 
right for which no complaint has been lodged by the holder thereof in accordance with subsection (1) 
of this section. 
Section 34. (1) The owner of an intellectual property right, who has valid grounds for suspecting that 
the importation of counterfeit goods may take place, may apply to the Commissioner in the prescribed 
manner to seize and detain all suspected counterfeit goods which are— 
(a) goods   featuring,   bearing,   embodying or incorporating the subject matter of that intellectual 
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property right or to which the subject matter of that right has been applied; and 
(b) into or enter Kenya during the period specified in the application: Provided that the period may 
not extend beyond the last day of the period for which that intellectual property right subsists. 
(2) For purposes of sub-section (1), the applicant may furnish to the Commissioner— 
(a) a specimen of the goods to which the subject matter of his relevant intellectual property right 
relates; 
(b) sufficient information and particulars as to— 
(i) the subsistence and extent of that intellectual property right; and 
(ii) his title to that right. 
(3) The Commissioner shall consider and deal with an application under sub-section (1) within three 
working days and may grant the application if satisfied on reasonable grounds that—  
(a) the goods claimed to be protected are prima facie protected goods; 
(b) the intellectual property right, the subject matter of which relates to the protected goods, prima 
facie subsists; and 
(c) the applicant prima facie is the owner of that intellectual property right. 
(4) When an application made under subsection (1) has been granted and notice thereof given under 
subsection (5), the counterfeit goods of the type with reference to which that application was made 
(hereafter called the stipulated goods), or suspected on reasonable grounds to be stipulated goods, 
and imported into or entering Kenya from time to time during the period determined by the 
Commissioner, which may be shorter than the period applied for, may be seized and detained by the 
customs authorities in accordance with the East African Community Customs Management Act, 2005 
subject to subsections (6) and (7).  
(5) The Commissioner shall, by notice in writing, inform the applicant whether the application has 
been granted or not, and—(a) if granted, state the period during which any stipulated goods being 
imported into or entering Kenya will be made subject to seizure and become subject to detention 
under subsection (4); 
(b) if not granted, state the reasons for refusal to be granted. 
(6) For purposes of acting under subsection (4) in relation to goods that are stipulated goods or 
suspected on reasonable grounds to be stipulated goods— 
(a) an authorized customs officer shall seize the counterfeit goods or alleged or suspected 
counterfeit goods, in accordance with subsection (1) or (4); 
(b) the following provisions will apply mutatis mutandis in relation to an authorized customs 
officer— 
(i) the provisions in accordance with or subject to which the powers contemplated in section 33 (4) 
may be exercised by an inspector so acting on his own initiative; 
(ii) the provisions by which any other power or any right, function, duty, obligation, exemption, 
indemnity or liability is conferred or imposed on an inspector so acting: Provided that the Minister, 
at the request of the Minister for the time being responsible for finance acting on the 
recommendation of the Commissioner, may, by notice in the Gazette, exempt an authorized customs 
officer from any of the provisions made applicable by this paragraph if satisfied that there are 
suitable and appropriate alternative arrangements made by or under the Customs Management Act, 
2005 that cover the purpose of the provision from which exemption is sought. 
(7) Any person who suffers damage or loss caused by wrongful seizure, removal or detention of goods 
alleged to be counterfeit goods pursuant to an application made to the Commissioner shall be entitled 
to claim compensation for the damage or loss suffered by him against the applicant: 
Provided that compensation shall only be paid where the application for seizure and detention was 
false or negligent or made in bad faith. 
(8) The provisions of this Act shall not be construed so as to render the customs authority or any of its 
staff or agents liable for— 
(a) any failure to detect or seize stipulated goods; 
(b) the inadvertent release of any such goods; or 
(c) any action taken in good faith in respect of such goods. 
(9) For purposes of this section, “customs authority” means the Kenya Revenue Authority established 
under the Kenya Revenue Authority Act (Cap. 469).  
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contended that the impugned provisions were inconsistent with the provisions of the 
Kenyan Constitution as they potentially hindered access to life-saving medications for 
HIV positive persons. In particular, the petitioners contended that the Anti-Counterfeit 
Act will have negative effects on the manufacturing and accessibility of cheaper generics 
drugs, thereby infringing their rights to life, dignity and health guaranteed under 
articles 26(1), 28 and 43 of the Constitution of Kenya.6 The petitioners then asked the 
court for the following orders: 
(1) A declaration that the fundamental rights to life, dignity and health 
guaranteed under  articles  26, 28 and 43 of the Kenyan Constitution 
encompass the right to affordable and accessible life-saving medications, 
including generic drugs; 
(2) A declaration that in so far the Anti-Counterfeit Act limits access to essential 
and affordable drugs and medicines, including generic drugs for HIV/AIDS, it 
constitutes an infringement of the petitioners’ rights to life, dignity and 
health all guaranteed under articles 26, 28 and 43 of the Kenya Constitution. 
(3) A declaration that the enforcement of the Anti-Counterfeit Act  in so far as it 
affected access to affordable and essential drugs and medications, 
particularly generic medicines, was a breach of the petitioners’ rights to life, 
dignity and health as guaranteed under articles 26(1), 28 and 43 of the 
Kenyan Constitution. 
(4) Any further orders, directions and declarations that the court may wish to 
make.7 
 
During the pendency of this case, a non-governmental organisation, AIDS Law Project, 
was joined as an interested party, while the United Nations (UN) Special Rapporteur on 
the Right to the Highest Attainable Standard of Health was admitted as an amicus.  
1.2 Decision  
After reviewing the evidence before it and listening to the arguments of lawyers, the 
court found that sections 2, 32 and 34 of the Anti-Counterfeit Act were inconsistent with 
articles 26(1), 28 and 43 of the Kenyan Constitution. The court further found that the 
Anti-Counterfeit Act threatened to limit access to affordable and essential drugs and 
medicines, including generic medicines for HIV and AIDS. According to the court, the 
provisions of the Act would seem to have defined ‘counterfeit’ broadly such that it may 
encapsulate generic medicines. This is not only misleading but also dangerous as it may 
lead to a situation where generic medicines are classified as counterfeit and therefore 
                                                 
6 Article  26(1)(1) Every person has the right to life,  
Article 28 Every person has inherent dignity and the right to have that dignity respected and protected,  
Article 43(1) Every person has the right— 
(a) to the highest attainable standard of health, which includes the right to health care services, including 
reproductive health care; 
(b) to accessible and adequate housing, and to reasonable standards of sanitation; 
7 PA.O and others v Attorney General and another  para 2. 
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subject to criminalisation. The corollary of this is limited access to cheaper life-saving 
medicines. The court further reasoned that though the government may have a genuine 
intention to protect the public from the menace of substandard drugs, such an intention 
must be balanced with the rights of the citizens. The court advised that it was 
‘incumbent on the states to reconsider the provision of section 2 of the Anti-Counterfeit 
Act along its constitutional obligation to ensure that citizens have access to the highest 
attainable standard of health. . .’8  
2 HIV/AIDS SITUATION IN KENYA  
Before going into the analysis of the decision of this case, it is important to understand 
the context in which the decision was made by examining the HIV/AIDS situation in 
Kenya. This will provide an important background to the filing of the case and the 
decision reached by the court. In the early years of the HIV/AIDS epidemic around 1983 
to 1985 only 26 cases of HIV/AIDS infections were reported in Kenya.9 By the end of 
1987 this has increased to about 288 cases with prevalence highest among sex 
workers.10 Over the years the Kenyan government has taken various steps to respond to 
the HIV/AIDS epidemic. The government’s response to the epidemic is coordinated by 
the National AIDS Control Council (NACC) which was established in 1999. At the end of 
2011 an estimated 1.6 million people were said to be living with HIV in Kenya. Of this 
figure, an estimated 500,000 people (about 75%) in need of HIV treatment were 
receiving it.11 This is a significant achievement for the government as compared to other 
countries in Africa. It should be noted that one of the key pillars of the Kenya National 
HIV and AIDS Strategic Plan for 2010-2013 (KNASP III) is the provision of cost-effective 
prevention, treatment, care and support services, informed by an engendered rights-
based approach, to realise universal access. Towards this goal government has laid 
emphasis on improving the coverage of antiretroviral therapy to reach rural 
communities and scaling-up services in relation to the prevention of mother-to-child-
transmission of HIV. 
With regard to prevention of mother-to-child transmission of HIV, an estimated 
69% of HIV-positive pregnant women were said to be receiving treatment in 2011.12 
Since 2000 prevention of mother-to-child transmission services has increased greatly. 
Indeed, the treatment programme of the Kenyan government has improved 
considerably over the years. It is currently estimated that there are now more than 
3,397 health facilities offering PMTCT services in country.13 When it first started few 
years back, the number of people receiving treatment, like in many other African 
                                                 
8 PA.O and others v Attorney General and another  para 88.                                        
9 AIDS Newsletter (1987) ‘Military service in Kenya: AIDS risk’, Item 14, 15th January 1987. 
10 AIDS Newsletter (1987) ‘Africa’, Item 181, 23rd March 1987. 
11 Kenya National AIDS Control Council ‘Kenya AIDS epidemic update report’ Kenya National AIDS Control 
Council 2012. 
12 Ibid. 
13 United Nations General Assembly Special Session on HIV and AIDS (UNGASS 2010) Country Report for 
Kenya (Kenya National AIDS Control Council, NACC (2010). 
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countries, was very low. For instance as at 2003 only 5% of those in need of HIV 
treatment was receiving it.14 However, over the last few years the government has 
renewed its commitment to combating the epidemic and has been able to secure 
support from various donor institutions and some developed countries to scale up 
access to HIV treatment significantly.  In 2006 the Kenyan government announced that 
antiretroviral drugs will be provided free for those in need at public hospitals and 
health centres.15 This was a significant move given that majority of those in need of 
treatment during the time lacked access.  The development has in turn led to a drastic 
reduction (about 50%) in number of people dying from HIV-related complications.  
While this modest progress is commendable, the Kenyan HIV treatment 
programme continues to face series of challenges. In particular, universal access to life-
saving medications for people in rural areas is hindered by HIV-related stigma and 
discrimination and incoherent policy formulation and implementation. Moreover, 
access to treatment for vulnerable groups such as children and sex workers is still poor. 
It is estimated that only 31% of children in need of treatment are receiving it.16Perhaps 
one of the biggest concerns relating to access to HIV treatment in Kenya is the weak 
healthcare system often as a result of the shoe-string budget allocation by government 
to the health sector.17 It should be noted that about 80% of the resources for HIV 
treatment in Kenya come from donor organisations and developed countries.18 This 
clearly makes the country highly vulnerable in terms of ensuring the sustainability of 
the HIV treatment programme. In recent times, allocation by the Kenyan government to 
the health sector has hovered around 5-6%, while specific spending on HIV has 
continued to decrease below 25% since 2007.19 This is a major cause for concern and 
would seem to imply that the government is taking a retrogressive step towards the 
realisation of the right to health. It would be recalled that in 2001 during the Abuja 
Declaration, African governments committed themselves to allocating at least 15% of 
their annual budgetary allocations to the health sector.20 
3 ACCESS TO MEDICINES AS A HUMAN RIGHT  
One of the issues raised in this case relates to the importance of access to medicine as a 
fundamental human right. It is now widely agreed that access to medicines constitute an 
integral part of the right to health.21 During the UN General Assembly Special Session on 
                                                 
14 WHO/UNAIDS/UNICEF Towards Universal Access: Scaling up priority HIV/AIDS Intervention in the 
Health Sector (Geneva: WHO, 2007)   
15 BBC News ‘Kenya to provide free AIDS Drugs’ available at  
http://news.bbc.co.uk/2/hi/africa/5040240.stm (reported on 2 June 2006). 
16 UNAIDS  ‘Report On The Global AIDS Epidemic’ (Geneva, UNAIDS, 2012) 
17 Ibid. 
18 Ibid.  
19 Ibid. 
20African Summit on HIV/AIDS, Tuberculosis and other Related Infectious Diseases, Abuja-Nigeria April 
24-27 2001 OAU/SPS/ABUJA/3. 
21 See for instance, Durojaye E ‘Advancing gender equity in access to HIV Treatment through the Protocol 
to the African Charter on the Rights of Women (2006 ) African Human Rights Law Journal 187; see also, 
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HIV& AIDS in 2001,22 the international community reaffirmed that access to medicine, 
particularly HIV medicines, for those in need,  constitutes a fundamental human right.  
This position was echoed by the UN General Assembly during the Political Commitment 
in 201123 where the international community committed to ensuring access to HIV 
medicines to 15 million people by 2015.  
It should be noted that the right to health is explicitly guaranteed in numerous 
human rights instruments such as article 12 of the International Covenant on Economic, 
Social and Cultural Rights24 (ICESCR), article 12 of the Convention on Elimination of All 
Forms of Discrimination against Women25 (CEDAW) and article 24 of the Convention on 
the Rights of the Child26 (CRC). By far the most authoritative provision on the right to 
health is found in article 12 of the ICESCR.27 It guarantees the right of the highest 
attainable standard of health for everyone. In addition, article 12 (2) of the same 
provision recognises the relevance of the underlining determinant of the right to health 
such as access to clean environment, child and maternal health, and safe drinking water. 
The Committee on Economic, Social and Cultural Rights (CESCR) has explained 
that the right to health includes both freedoms and entitlements.28According to the 
Committee, ‘freedoms’ implies that states should not interfere with individuals‘ 
autonomy to consent to medical treatments, while ‘entitlements’ imposes obligations on 
states to ensure the provision of health facilities, goods and services, including essential 
medicines. The CESCR has further explained that access to essential medicines 
constitute a minimum core of the right to health. This implies that states parties to the 
Covenant cannot on the excuse of lack of resources fail to make available life-saving 
medications for those in need. This will not only amount to the violation of the right to 
health, but also infringe the right to life. Indeed, the CESCR in its General Comment 14 
has explained that the enjoyment of the right to health is dependent on other human 
                                                                                                                                                        
Hongerzeil HV et al ‘Is Access to essential medicines as part of the fulfillment of the right to health 
enforceable through the courts?’ (2006) 360 Lancet 305. 
22 UN General Assembly Special Session on HIV/AIDS Resolution A/S-26/L2 June 2001 para 15. 
23 UN General Assembly Session 2011. 
24 International Covenant on Economic, Social and Cultural Rights, U.N. Doc.A/6316 (1966). 
25 Convention on Elimination of All Forms of Discrimination against Women (CEDAW)G.A. res. 34/180, 34 
U.N. GAOR Supp. (No. 46) at 193, U.N. Doc. A/34/46, entered into force Sept. 3, 1981. 
26 International Convention on the Rights of the Child (CRC), U.N. Doc. A/RES/44/25, 1989. 
27 International Covenant on Economic, Social and Cultural Rights, Article 12 (1) ‘The States Parties to the 
present Covenant recognize the right of everyone to the enjoyment of the highest attainable standard of 
physical and mental health.  (2) The steps to be taken by the States Parties to the present Covenant to 
achieve the full realization of this right shall include those necessary for:  
(a) The provision for the reduction of the stillbirth-rate and of infant mortality and for the healthy 
development of the child;   
(b) The improvement of all aspects of environmental and industrial hygiene;   
(c) The prevention, treatment and control of epidemic, endemic, occupational and other diseases;   
(d) The creation of conditions which would assure to all medical service and medical attention in the 
event of sickness.   
28 UN Committee on Economic, Social and Cultural Rights (CESCR)  General Comment No 14: The Right to 
the Highest Attainable Standard of Health, UN Doc E/C/12/2000/4. 
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rights, such as rights to human dignity, privacy, non-discrimination and life.29 Other 
commentators have echoed this view. For instance, Yamin has argued that the denial of 
life-saving medications for people living with HIV will constitute the violation of the 
right to life.30 
At the regional level, the right to health is guaranteed in the African Charter on 
Human and Peoples' Rights 31 (African Charter).32 The wording of that provision is 
almost similar to that of article 12 of the ICESCR. Also, article 14 of the Protocol to the 
African Charter on the Rights of Women33 (African Women’s Protocol) explicitly 
guarantees the right to health, including sexual and reproductive health and rights of 
women.34 Article 14 is one of the most detailed provisions on the right to health of 
women, including sexual and reproductive health. The provision for the first time 
affirms sexual and reproductive health as human rights, and provides for the autonomy 
of women to seek information and services relating to contraception, enjoy safe 
maternal health and seek abortion services on certain grounds. 
                                                 
29 Ibid. 
30 Yamin AE ‘Not Just a tragedy: access to medications as a right under international law’ 21 Boston 
University International Law Journal 325 -371. See also Durojaye E ‘Compulsory Licensing and Access to 
medicines in post Doha Era: What hope for Africa? (2008) 51 Netherlands International Law Review 33-
72; Hongenzeil et al note 21 above. 
31African Charter on Human and Peoples' Rights (Adopted 27 June 1981, OAU Doc. CAB/LEG/67/3 rev. 5, 
21 I.L.M. 58 (1982), entered into force 21 October 1986). 
32 African Charter on Human and Peoples' Rights, Article 16(1) Every individual shall have the right to 
enjoy the best attainable state of physical and mental health. 2. States Parties to the present Charter shall 
take the necessary measures to protect the health of their people and to ensure that they receive medical 
attention when they are sick. 
33 Protocol to the African Charter on the Rights of Women. (Adopted by the 2nd Ordinary Session of the 
Assembly of the Union, Maputo, CAB/LEG/66.6 (Sept. 13, 2000) entered into force 25 November 2005.) 
34 Protocol to the African Charter on the Rights of Women Article 14: Health and Reproductive Rights (1) 
States Parties shall ensure that the right to health of women, including sexual and reproductive health is 
respected and promoted. This includes: 
a) the right to control their fertility; 
b) the right to decide whether to have children, the number of  children and the spacing of children; 
c)  the right to choose any method of contraception; 
d)  the right to self-protection and to be protected against sexually transmitted infections, including 
HIV/AIDS; 
e)  the right to be informed on one's health status and on the health status of one's partner, particularly 
if affected with  sexually transmitted infections, including HIV/AIDS, in accordance with internationally 
recognised standards and best practices; 
g) the right to  have family planning education. 
2.  States Parties shall take all appropriate measures to: 
a)  provide adequate, affordable and accessible health services, including  information, education and 
communication programmes to women especially those in rural areas;  
b)  establish and strengthen existing pre-natal, delivery and post-natal health and nutritional services 
for women during pregnancy and while they are breast-feeding; 
c)  protect the reproductive rights of women by authorising medical abortion in cases of sexual assault, 
rape, incest, and where the continued pregnancy endangers the mental and physical health of the 
mother or the life of the mother or the foetus. 
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The African Commission on Human and Peoples’ Rights (African Commission) in 
Purohit and Moore v The Gambia35 has explained that the provision of article 16 of the 
African Charter imposes obligation on states to ensure that access to health-related 
goods and services (including access to medicines) is guaranteed to all without 
discrimination. In addition, the African Commission has noted that realising access to 
life-saving medications is a human rights issue and thus urges states to take necessary 
steps to facilitate access to life-saving medications for their citizens. It should be noted 
that Kenya has ratified most of the human rights instruments mentioned above. 
Therefore, the country is obligated to fulfil the provisions of these instruments. 
Despite these copious provisions on the right to health at the international and 
regional levels, access to medicines, particularly life-saving medications in the context 
of HIV/AIDS has remained a great challenge in many African countries, including Kenya. 
While it should be noted that the number of people receiving HIV treatment has 
improved considerably compared to 10 years ago, a significant number of people still 
lack access to life-saving medication. Currently, it is estimated that eight million people 
out of 15 million in need of HIV treatment across the world, are receiving it.36 About six 
million of those receiving treatment are from Africa.37 This is a significant improvement 
compared to 2004 when only about 440,000 people were said to be receiving treatment 
across the world.38 The improvement in the number of people receiving treatment 
across the world particularly in Africa is attributed to donor institutions and 
governments, such as the Bill and Melinda Gates Foundation,39 Clinton Foundation,40 the 
Global Fund to Fight AIDS, Tuberculosis and Malaria41 and the United States President's 
Emergency Plan for AIDS Relief (PEPFAR).42 
While the above developments are commendable, challenges remain regarding 
the scaling-up of HIV treatments in Africa. Indeed, disparities exist across the region as 
regards the number of people receiving treatment, particularly in relation to the 
prevention of mother-to-child transmission of HIV. While many of the countries in the 
southern part of the region, such as, Botswana, Namibia and South Africa have achieved 
universal access as regards prevention of mother-to-child transmission, their 
counterparts in other sub-regions such as West Africa are still lagging behind.43 The 
revised Guideline 6 of the International Guidelines on HIV/AIDS and Human Rights44 
                                                 
35Purohit and Moore v.The Gambia African Communication No. 241/2001 (2003). 
36 UNAIDS Together we Will End AIDS (Geneva UNAIDS 2012) 9 (UNAIDS / JC2296E) 
37 Ibid. 
38 UNAIDS/WHO AIDS Epidemic Update (Geneva, UNAIDS 2004) 6. 
39 Bill and Melinda Gates Foundation (www.gatesfoundation.org/) 
40 Clinton Foundation  (www.clintonfoundation.org/) 
41 The Global Fund to Fight AIDS, Tuberculosis and Malaria (www.theglobalfund.org/). 
42 The United States President's Emergency Plan for AIDS Relief (PEPFAR) (www.pepfar.gov/). 
43 UNAIDS ‘Global AIDS Epidemic Report’ (Geneva, UNAIDS 2010) 99. 
44 International Guidelines on HIV/AIDS and Human Rights (U.N.C.H.R. res. 1997/33, U.N. Doc. 
E/CN.4/1997/150 (1997). 
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enjoin states to review and, where necessary, amend or adopt laws, policies, 
programmes and plans to realise universal and equal access to medicines...’.45 
It should be noted that the bulk of HIV medicines supplied to the Kenyan 
treatment programme are generic drugs rather than patented,46 which account for the 
wide coverage of the treatment programme. Therefore, the introduction of the Anti-
Counterfeit Act constitutes a major threat to access to HIV treatment and may 
undermine the rights of people living with HIV in Kenya. As rightly pointed out by the 
court, a state is under obligations to respect, protect and fulfil the right to health, 
including access to medicines for its citizens. A violation of the obligation to respect will 
occur if a state adopts any policy or measure, which may prevent its citizens from 
realising this right. 
In one of its resolutions on access to medicine in Africa, the African Commission 
has enjoined states to refrain from taking steps that will hinder access to medicines for 
their citizens.47Also, the African Commission notes that states should always give 
priority to their obligations with respect to the right to health above any other 
considerations. The African Commission particularly emphasizes that African 
government must refrain from ‘implementing intellectual property policies that do not 
take full advantage of all flexibilities in the WTO Agreement on Trade-Related Aspects of 
Intellectual property Rights (TRIPS), that promote access to affordable medicines, 
including “TRIPS-Plus” trade agreement’.48 
The petitioners in P.A.O claimed that the Anti-Counterfeit Act threatened their 
rights to life, dignity and health. Besides the problem of prevention of mother-to-child 
transmission of HIV, there are also concerns that some of the people on treatment in 
Kenya might develop resistance to first line treatment. The implication of this is that 
sooner or later, most people will have to move to second line treatment. These drugs 
are more expensive than those for the first line treatment due to the fact that most of 
them (second line drugs) are patented. This underlines the importance of ensuring 
access to generic medicines for people living with HIV. The petitioners in the P.A.O case 
had argued along this line and the court upheld the argument. By so doing, the court 
would seem to be suggesting that the Kenyan government would need to take more 
drastic steps to remove barriers to cheaper medications for its citizens. This is 
consistent with the government’s obligations to promote and protect the right to health.  
                                                 
45 International Guidelines on HIV and Human Rights, Guideline 6 (as revised in 2002): ‘States should 
enact legislation to provide for the regulation of HIV-related goods, services and information, so as to 
ensure widespread availability of quality prevention measures and services, adequate HIV prevention 
and care information, and safe and effective medication at an affordable price.  States should also take 
measures necessary to ensure for all persons,  on a sustained and equal basis, the availability and 
accessibility of  quality goods, services and information for HIV prevention, treatment, care and 
support, including antiretroviral and other safe and effective  medicines, diagnostics and related 
technologies for preventive, curative  and palliative care of HIV and related opportunistic infections and  
conditions.  States should take such measures at both the domestic and international levels, with 
particular attention to vulnerable individuals and populations.’. 
46 As above note 13.  
47 African Commission on Human and Peoples’ Rights ACHPR/Res.141 (XXXXIIII) 08: Resolution on 
Access to Health and needed Medicines in Africa. 
48 Ibid. 
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4 INTELLECTUAL PROPERTY RIGHTS VERSUS HUMAN RIGHTS  
For so many years, the debate has raged on as to whether or not patent rights constitute 
barriers to access to HIV treatment in developing countries. On the one hand, 
pharmaceutical companies have argued that there is no correlation between patent 
rights and access to treatment, noting that even if drugs were not patented in the region, 
access to treatment will remain a challenge due to poor facilities, dearth of skilled 
health personnel, lack of resources and corruption. In addition, they have argued that 
manufacturing of drugs is capital intensive and requires long years of investment in 
research and development (R&D).49 Therefore, they submit that unless patent is 
guaranteed for manufactured drugs further research into new drugs will be impossible 
due to lack of incentive.50 
On the other hand, people living with HIV and commentators have expressed the 
views that patent rights, particularly on pharmaceutical products, constitute great 
barriers to life-saving medications in Africa.51 This argument would seem to have been 
supported by a study carried out by the Commission on Intellectual Property Rights52 
where it was found that patent rights on pharmaceutical products often lead to high 
cost of drugs and do constitute barriers to access to treatment in poor regions.53While it 
is true that patent protection is by no means the only barrier to access to medicines, 
undoubtedly patents play a crucial, if not determinant, role in limiting access to life-
saving medications in the context of HIV.54In response to pharmaceutical companies’ 
argument that patent rights encourages R&D, it has been noted that sub-Saharan Africa 
merely accounts for about 2 per cent of total profits derived from patented drugs and 
that if there were no patent protection in Africa, and no sales by pharmaceutical 
companies, their profits from drugs will by no means be affected.55Moreover, it has been 
contended that patents do not necessarily promote R & D56 and that funding for R&D in 
some developed countries such as America are borne by public institutions.57 Therefore, 
                                                 
49 International Intellectual Property Institute (IIPI), Patent Protection and Access to HIV/AIDS 
Pharmaceuticals in Sub-Saharan Africa (Washington, DC, IIPI 2000) p. 24. 
50 Ibid 
51 See Osewe P et al Improving Access to HIV Medicines in Africa: Trade Related Aspect of Intellectual 
Property Rights Flexibilities (2008); see also,  Berger J ‘Tripping over Patents: AIDS, Access to Treatment 
and the Manufacturing of Scarcity’, 17 (2002) Connecticut Journal of International Law 157; 
Hestermeyer, H Human Rights and the WTO: The Case of Patents and Access to Medicines (Oxford: Oxford 
University Press 2007) 154. 
52 See Commission on Intellectual Property Rights (independent commission set up by British 
government), Final Report, September 2002, available at <www.iprcommission.org> (Accessed on 3 
September 2012). 
53 Berger note 51 above; Durojaye note 30 above. 
54 See Osewe et al note 51 above. 
55 See for instance, Boulet, P.et al., Drug Patents under the Spotlight: Sharing Practical Knowledge about 
Pharmaceutical Patents (Geneva, MSF 2003) 6. 
56 WHO Commission on Intellectual Property Rights, ‘Innovation and Public Health, Framework paper’, 
July 2004, available at <www.who.int/intellectualproperty/documents/thereport/CIPIH23032006.pdf 
(accessed on 4 September 2012) 
57 Foreman M. et al, Beyond Our Means? The Cost of Treating HIV/AIDS in the Developing Countries(London, 
Panos Institute 2000) at 1. 
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it is misleading to argue that R&D promote costs necessitate patent rights on life-saving 
drugs. 
It must be recalled that during the negotiation for the World Trade 
Organisation’s (WTO) agreement on Trade Related Aspects of Intellectual Property 
Rights (TRIPS),58 developing countries had expressed scepticism regarding a need for 
strong intellectual property regime on pharmaceutical products. This is because many 
of the developing and least developed countries lack the capacity to manufacture 
pharmaceutical products. Eventually, however, developing and least developed 
countries were strongly persuaded by developed countries based on the promise that 
they(developing and least developed countries) will receive subsidies on agricultural 
products.   
It should be noted that despite the strong intellectual property regime imposed 
by the TRIPS Agreement, member states have some latitudes to make use of the 
flexibilities contained therein. Some of which include compulsory licencing, parallel 
importation and bolar exception.59However, the major challenge with the use of the 
flexibilities in the TRIPS Agreement has remained stiff opposition from developed 
countries and pharmaceutical companies. In most cases developed countries backed by 
the United States have argued that the use of compulsory licensing to facilitate the 
manufacture of generic drugs will not only erode patent rights of pharmaceutical  
companies, but may also encourage manufacturing of substandard drugs.60 Attempts by 
countries, such as, South Africa, Thailand and India to invoke the flexibilities in the 
TRIPS agreement have all been met with opposition and threats from developed 
countries, particularly the United States.61 Kenya is a member of the WTO and in line 
with its obligation under the TRIPS Agreement enacted the Intellectual Property Act. 
                                                 
58 The TRIPS Agreement was part of the Final Act establishing the WTO commonly referred to as the 
‘Marrakech Agreement’, attached as Annex 1C to the WTO Agreement. 
59 (i) Compulsory licensing-refers to the mechanism used by public authorities to authorize use of a 
patent-protected invention by the government or third parties without the consent of the patent-
holder. Usually compensation is paid to the patent holder.  
(ii) Parallel importation- refers to a situation whereby a country with limited resources can sometimes 
afford more of a patented medicine by purchasing it abroad at a lower price and importing it, rather 
than buying it directly in its domestic market at the higher price. 
(iii) Bolar exception- This permits the use of a patented invention without authorization from the patent 
owner in order to obtain marketing approval of a generic product before the patent expires. This allows 
a generic product to enter the market more quickly after patent expiry, which in turn facilitates access 
to cheaper medicines. 
60 See Durojaye E TRIPS, Human Rights and Access to Medicines in Africa: A Post Doha Analysis (VDM Verlag 
Dr. Müller  Press 2010). 
61 The case of the 39 pharmaceutical companies that sued the South African government for introducing a 
law that permits the use of compulsory licensing and parallel imports in 1998, see Pharmaceutical 
Manufacturers’ Association of South Africa v President of the Republic of South Africa , Case No 4183 of 
1998. The Thai government has also been challenged and threatened by Abbot, one of the big 
pharmaceutical companies for invoking the use of compulsory licensing to facilitate access to a cancer 
drugs for which Abbot owed the patent. More recently, Indian government has been challenged by 
Novartis for adopting a strict requirement for renewal of patent in its recent patent law. The Supreme 
Court of India has rejected the patent application filed by Novartis. See Novartis v Union of India & 
Others Supreme Court of India Civil Appeal No. 2706-2716 of 2013, available at 
http://supremecourtofindia.nic.in/outtoday/patent.pdf. (accessed 22 April 2013). 
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While the Act recognises patent rights on medicines, it empowers the Kenyan 
government to invoke some measures such as parallel importation and compulsory 
licensing to facilitate access to cheaper drugs for the citizens.  
Experience has shown that generic drugs cost far less than patented drugs and 
they are accessible and affordable for majority of people in need. A study has shown 
that generic drugs cost 10 times less than patented drugs.62 This is a clear indication 
that the invocation of the flexibilities in the TRIPS Agreement in order to facilitate 
access to generic drugs is consistent with the realisation of the right to health as 
guaranteed under the international human rights law. It would be recalled that during 
the Ministerial Council Meeting of WTO in 2001 (Doha Declaration), it was affirmed that 
member states have the right to invoke the flexibilities in the TRIPS Agreement in order 
to address public health emergency.63 
More importantly, it was affirmed that member states are at liberty to decide 
when they can use compulsory licensing in order to facilitate access to cheaper 
medicines for their citizens. While it remains debatable whether the Doha Declaration 
constitutes a binding obligation on states, it is incontestable that the Declaration 
imposes moral obligations on member states of WTO to ensure that the TRIPS 
Agreement is implemented in a way that advances public health. 
It is sad to note that more than a decade after the Doha Declaration, developed 
countries and pharmaceutical companies have remained stumbling blocks to 
availability, accessibility and affordability of life-saving medications, particularly in the 
context of HIV/AIDS. Worse still, some developed countries, including members of the 
European Union (EU), have resorted to bullying tactics with a view to pressurising some 
developing and least developed countries to adopt stricter intellectual property rights 
regimes than envisaged by the TRIPS Agreement. This is commonly referred to as 
TRIPS-plus. One of such approaches is to request developing or least developed 
countries to enact anti-counterfeit laws to deal with substandard drugs. The facts of the 
P.A.O case bring to the fore once more this contentious issue. It should be noted that the 
Kenyan government through the Intellectual Property Act has incorporated some of the 
flexibilities in the TRIPS agreement into its domestic law. This piece of legislation 
permits Kenyan government to invoke the use of compulsory licensing and  parallel 
importation in order to facilitate access to cheaper generic medicine for those in need. 
This is a welcome development and would seem to portray the Kenyan government as 
willing to advance the right to health of its citizens. 
While it is agreed that the issue of substandard drugs is a challenge in many 
African countries and needs to be addressed, the problem, however,` is that the so-
called anti-counterfeit laws being proposed by developed countries tend to give a broad 
definition of what amounts to counterfeit drugs. Indeed, some of these laws define 
                                                 
62 WTO, Doha Ministerial Declaration on the TRIPS Agreement and Public Health, WTO Doc. No. 
WT/MIN(01)/DEC/2 (2001) para 4. 
63 T Heon E.F.M The Global Politics of Pharmaceutical Monopoly Power: Drug patents, access, innovation 
and the application of the WTO Doha Declaration on TRIPS and Public Health (Netherlands: AMB 
Publishers, 2009) 25. 
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counterfeit drugs to include generic medicines. A good example is the Kenya Anti-
Counterfeit Act,64 which was the bone of contention in this case. According to section 2 
of the Act, ‘counterfeit’ is defined to mean  (a) ‘the manufacture, production, packaging, 
re-packaging, labelling or making, whether in Kenya or elsewhere, of any goods 
whereby those protected goods are imitated in such manner and to such a degree that 
those other goods are identical or substantially similar copies of the protected goods;’65 
(d) ‘in relation to medicine, the deliberate and fraudulent mislabelling of medicine with 
respect to identity or source, whether or not such products have correct ingredients, 
wrong ingredients, have sufficient active ingredients or have fake packaging.’66 
The petitioners in this case argued that this definition is too broad and would 
seem to have subsumed genetic medicines under the term ‘counterfeit’. It was therefore 
argued that such a broad definition is not only misleading, but also capable of limiting 
access to life-saving medications to those in need. As noted earlier, generic drugs are 
cheaper than patented medicines and given the fact that most of the HIV drugs used in 
Kenya are generic rather than patented, the provisions of the Anti-Counterfeit Act were 
likely to be counterproductive. More importantly, the petitioners contended that this 
provision would infringe the rights to life, dignity and health guaranteed under the 
Kenyan Constitution.67 
In agreeing with the petitioners, the judge held that the language of the Anti-
Counterfeit Act would seem to be overly broad and amount to a sweeping 
generalisation by classifying generic drugs as counterfeits. Using the rights-based 
approach, the judge reasons that the Kenyan government is obligated under 
international human rights law and the national Constitution to respect the rights to life, 
dignity, and health of its citizens. This obligation requires the Kenyan government to 
refrain from taking any steps, including the enactment of any law that will hinder access 
to life-saving medications for the people. The court also noted that while it is desirable 
to protect the public from counterfeit goods, and preserve the right of pharmaceutical 
companies to enjoy patent rights, this must be weighed against a state’s obligation not 
to interfere with the enjoyment of the rights of its citizens. According to the court: 
“the rights to life, dignity and health of people like the petitioners who are infected with the HIV 
virus [sic] cannot be secured by a vague proviso in a situation where those charged with the 
responsibility of enforcement of the law may not have a clear understanding of the difference 
between generic and counterfeit medicine.”68 
To buttress this argument, the court relied on the interpretation provided by the 
Committee on Economic, Social and Cultural Rights (CESCR) in its General Comment 
1469 on the right to health, and General Comment 1770relating to the interpretation of 
                                                 
64 Kenya Anti-Counterfeit Act 2008.  
65 Section 2(a) Kenya Anti-Counterfeit Act 2008. 
66 Section 2(d) Kenya Anti-Counterfeit Act 2008. 
67 The rights to life, dignity and health guaranteed under the Kenyan Constitution article 26. 
68 PA.O and others v Attorney General and another  para 84. 
69 UN Committee on Economic, Social and Cultural Rights (CESCR)   General Comment 14 note 28 above. 
70 UN Committee on Economic, Social and Cultural Rights (CESCR)   General Comment 17 The right of 
everyone to benefit from the protection of the moral and material interests resulting from any scientific, 
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article 15 (1) (c) of the ICESCR. According to the court, while it is agreed that intellectual 
property rights are recognised as human rights, the enjoyment of such rights must be 
balanced with the enjoyment of crucial rights such as rights to life, dignity and health.  
More importantly, and as noted by the Committee on Economic, Social and 
Cultural Rights (CESCR)  in its General Comment 17, while the enjoyment of intellectual 
property rights is ephemeral, human rights are inalienable, indivisible and limitless.71 
The court further states that: 
“It would be in violation of the state’s obligations to the petitioners with respect to their right to 
life and health to have included in legislation ambiguous provisions subject to the interpretation 
of intellectual property holders and customs officials when such provisions relate to access to 
medicines essential for the petitioners’ survival.”72 
There is a growing consensus at international law level that respect for human rights 
should supersede trade agreements including the TRIPS Agreement. This is bolstered by 
the argument that article 103 of the UN Charter provides that states’ obligations under 
other treaties should not conflict with their obligations under the Charter.73 Given that 
the UN Charter is founded on the respect for human rights of all individuals, it can be 
argued that a state cannot assume any obligation under trade agreements, including the 
TRIPS Agreement that will be inconsistent with its obligation under the UN Charter. 
Furthermore, Forman has argued that states’ obligations with regard to ensuring access 
to medicines is of a higher threshold than obligations under trade agreements, including 
TRIPS, since the former will implicate the right to life which is regarded as the most 
fundamental of all human rights.74The UN Sub- Commission on Human Rights has noted 
that there is bound to be a conflict between the implementation of intellectual property 
rights agreements and human rights treaties.75 It therefore urges states to ensure that 
their obligations to safeguard human rights are not sacrificed at the altar of trade 
agreements such as the TRIPS.  
5 LESSONS FROM THE DECISION IN PAO CASE  
The court’s decision in the P.A.O case has come at a time when many African countries, 
including Kenya, still struggle to realise access to medicines for their citizens. Perhaps 
with the exception of South Africa, many countries in Africa have not really taken 
seriously the issue of access to medicines as a fundamental human right. This is 
                                                                                                                                                        
literary or artistic production of which he or she is the author (article 15, paragraph 1 (c), of the 
Covenant) 12 January 2006, U.N Doc. E/C.12/GC/17, available at: 
http://www.refworld.org/docid/441543594.html [accessed 22 April 2013]. 
71 UN Committee on Economic, Social and Cultural Rights (CESCR)  General Comment 17, para 2. 
72PA.O and others v Attorney General and another  para 84. 
73 Charter of the United Nations, 26 June 1945 (entered into force 24 October 1945), TS 67(1946). 
74 Forman, L, ‘Trade Rules, Intellectual Property and the Right to Health’  (2007)  21 Ethics and 
International Affair 337; see also, Cullet P, ‘Patents and Medicines: The Relationship between TRIPS and 
Human Rights to Health’,  (2003) 79 International Affairs 140. 
75 UN Sub-Commission on the Promotion and Protection of Human Rights. “Globalization and its impact 
on the full enjoyment of all human rights.” Resolution 2001/5 (15 Aug 2001), UN Doc 
E/CN.4/Sub.2/Res/2001/5. 
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worrisome given that Africa remains home to the largest number of people living with 
HIV in the world. It would be recalled that in 2001 African governments declared 
HIV/AIDS a state of emergency in the region and called for concerted efforts to mitigate 
its impact on the continent.76 While it is noted that few constitutions in Africa explicitly 
recognise the right to health, the fact that the right to health also intersects with other 
rights, such as, life, dignity and discrimination, makes it imperative for African 
governments to take the issue of access to medicines very seriously.77 It is sad to note 
that despite the flexibilities contained in the TRIPS Agreement - affirmed during the 
Doha Declaration- very few African counties have made attempts to either incorporate 
these flexibilities in their national laws or even invoked them to facilitate access to 
generic medicines for their citizens.  
One of the important lessons that can be learnt from this case is that it reaffirms 
the viability of litigation in advancing social rights and justice. Gloppen has argued that 
health rights litigation can be useful in holding a government accountable for its failure 
to realise the right to health within its jurisdiction.78 Her argument is based on the fact 
that people and institutions entrusted with powers and responsibilities have the 
obligation to justify that those powers and responsibilities have been used 
appropriately. Hogerzeil et al79 have similarly argued that ‘Skilful litigation can help to 
ensure that governments fulfil their constitutional and international treaty obligations. 
Such assurances are especially valuable in countries in which social security systems 
are still being developed. Other commentators, such as, Pieterse, have noted that social 
rights litigation, including health rights litigation, has the potential of advancing social 
justice and redistributing wealth in society, particularly among the poor.80  
A good example of a case where a government has been held accountable for its 
obligation to realise the right to health is the South African case of Minister of Health and 
ors v Treatment Action Campaign (TAC case).81 In that case, the South African 
Constitutional Court noted that the failure of the South African government to provide 
Nevaripine (NVP) widely in public care institutions for the purpose of preventing 
mother- to- child transmission of HIV amounts to a violation of the right to health as 
guaranteed in section 27 of the South African Constitution. This decision clearly 
exemplifies the point that the right to health imposes a positive obligation on a state to 
take appropriate measures and steps in order to ensure access to life-saving medication 
for its citizens. A point, which was reinstated in the P.A.O case when the court notes that 
the adoption of the Anti-Counterfeit Act by the Kenyan government would seem to be 
                                                 
76 Abuja Declaration  above  note 20. 
77 See Viljoen F, International human rights law in Africa (Oxford University Press, 2007).  
78 Gloppen S, ‘Litigating as a Strategy to Hold Government s Accountable for Implementing the Right to 
Health‘(2008) 10 Health and Human Rights 21. 
79 Hogerzeil H V  et al ‘Is Right to Essential Medicines as part of the Fulfillment of the Right to Health 
Enforceable through the Curt?’(2006)368 Lancet 305. 
80 See Pieterse M  ‘The Potential of Socio-economic Rights Litigation for the Achievement of Social Justice:: 
Considering the example of Access to Medical Care in South African Prisons’ (2006) 50 Journal of 
African Law 118; see also,  M Heywood ‘South Africa’s Treatment Action Campaign: Combining Law and 
Social Mobilisation to Realise the Right to Health’ (2009) 1 Journal of Human Rights Practice 24. 
81 Minister of Health v Treatment Action Campaign and Others 2002 10 BCLR 1033 (CC). 
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inconsistent with its obligations to realise the rights to life, dignity and health of its 
citizens.  
Another important lesson learnt from this case is that health rights litigation may 
be initiated by few individuals the outcome of the decision may impact positively on the 
lives of hundreds of people. From the fact of this case, it can been seen that the case was 
originally initiated by four petitioners but the outcome will no doubt benefit hundreds 
of Kenyans who are HIV positive and are qualified to be enrolled in the treatment 
programme. In other words, the outcome of social rights litigation goes beyond the 
original parties to the case but may have multiplier effects on the society as a whole, 
especially the vulnerable and marginalised groups. Affirming this point, Liebenberg has 
noted that litigating on socio-economic rights generally, and right to health in particular, 
has the potential of tangibly alleviating the suffering of vulnerable groups and ensuring 
them affirmative remedies that will satisfy their immediate vital needs within society.82  
A broad interpretation of P.A.O case would seem to suggest that the failure or 
reluctance of a government to invoke the flexibilities contained in the TRIPS Agreement 
to facilitate access to generic medicines for its citizens would amount to a violation of 
the obligation to safeguard the rights to health and life guaranteed in numerous human 
rights instruments. In the same vein, the recent development in some African countries 
where various forms of agreements, which impose stricter obligations than envisaged in 
the TRIPS Agreement (TRIPs plus) are being concluded, will also amount to a breach of 
the obligation to safeguard the rights to health and life under international human 
rights law. Article 66 of the TRIPS agreement read together with paragraph 7 of the 
Doha Declaration gives least developed countries in Africa the latitude not to be TRIPs 
compliant until 2016.83 Unfortunately, however, some of these least developed 
countries in Africa are already adopting TRIPS-complaint legislation. Moreover, some 
African countries have been reluctant in invoking the flexibilities contained in the TRIPS 
to facilitate access to life-saving medications for their people. Osewe et al have noted 
that obstacles to the use of flexibilities in TRPS in Africa are due to ignorance, lack of 
political will and poor or inefficient administrative structures.84 The implication is that 
in these countries access to essential medicine maybe difficult. As pointed out earlier, 
the African Commission has urged African countries to live up to their obligations with 
regard to realising access to medicine for their citizens. In particular, the reasoning of 
the African Commission in the Purohit 85case would seem to suggest that failure by 
African governments to provide access to medicines for vulnerable and marginalised 
groups such as people living with HIV would amount to a violation of the right to health 
                                                 
82 See S. Liebenberg, ‘Needs, rights and transformation: adjudicating social rights’ (2005) 8 Center for 
Human Rights and Global Justice Working Paper (Economic and Social Rights Series) 6–7. 
83 Many of these countries are  from Africa they include Angola, Benin, Burkina Faso, Burundi, Cape Verde, 
Central African Republic, Chad, Comoros, Democratic Republic of Congo, Djibouti, Equatorial Guinea, 
Eritrea, Ethiopia, The Gambia, Guinea, Lesotho, Liberia, Malawi, Mauritania, Mozambique, Niger, 
Rwanda, Sierra Leone, Togo, Uganda, Tanzania, and Zambia 
84 Osewe et al above note 48, xxi. 
85 Purohit v The Gambia above note 35. 
 LAW, DEMOCRACY & DEVELOPMENT/VOL 17(2013) 
 
Page | 42 
 
and constitute an act of discrimination contrary to articles 2 and 3 of the African 
Charter.  
Despite the positive nature of litigation in advancing social justice, it is important 
to note that victory in the courtroom does not necessarily translate to better living 
conditions for the people. In other words,too much hope should not be placed on social 
rights litigation , including health rights litigation. Goppen and Roseman have indeed 
cautioned that while health rights litigation has the potential of addressing social 
injustice, too much reliance should not be placed on it in order to avoid abuses or what 
has been referred to as the ‘epidemic of litigation’. 86 They made references to situations 
in Latin American countries where health rights litigation is being used constantly to 
address virtually all forms of shortcomings in the health sector. Ferraz has noted that 
while health rights litigation has increased over the years in Brazil, it is becoming clear 
that the main beneficiaries of these decisions are the middle class citizens and not 
necessarily the vulnerable and marginalised groups who often experience violations of 
their health rights.87 He therefore, warns that there is need for vigilance so that the 
courts do not become pawns in the hands of the rich and middle class in society.  
From the foregoing, a pertinent question that may arise from the P.A.O case will 
be: how will this case translate to meaningful results for hundreds of people living with 
HIV in Kenya? This is by no means an easy question to answer but it underscores the 
limitation of social rights litigation. Sometimes the much celebrated victory in court may 
mean little or nothing for the vulnerable and marginalised groups. This is because the 
government may either ignore or be slow in implementing the decision of the court. 
Thus, the poor and the marginalised may remain in the same situation they were before 
the decision of the court. In other words, access to essential services may remain a pipe 
dream for many in need of treatment.  It should be noted that the court merely made a 
declaratory order that the provisions of the Anti-Counterfeit Act are inconsistent with 
the Kenyan Constitution but fails to specifically order the government to amend the 
provisions of the law. The Court merely said that ‘it is incumbent on the state to 
consider’ the provisions of the offending sections of the Anti-Counterfeit Act. This is a 
bit problematic and may create uncertainty as to what the government should do and 
the time frame for implementing this decision. Given the importance of life-saving 
medications for the existence of people living with HIV in the country, one would have 
expected a more definite and precise order from the court. It may be argued though, 
that the court is only being cautious so as not to encroach into the precincts of the 
executive or legislature. However, much as the court should not interfere with the work 
of other organs of government, it has the responsibility to ensure that these other 
organs do not act contrary to their constitutional obligations.  
                                                 
86 S Gloppen & M.J. Roseman ‘Introduction: Can Litigation Bring Justice to Health?’ in S Gloppen & A Yamin 
(eds) Litigating Health Rights: Can Court Bring more Justice Health? (Harvard: Harvard Law School 
2011) 7 
87 Ferraz O.M.‘Brazil-Health Inequalities, Rights and Courts:  The Social Impact of Judicialisation of Health 
in in S Gloppen & A Yamin (eds) Litigating Health Rights: Can Court Bring more Justice Health? (Harvard: 
Harvard Law School 2011) 79-80; see also, V Gauri & D Brinks (eds) Courting Social justice: Judicial 
Enforcement of Social and Economic Rights in Developing World (Cambridge: Cambridge University 
Press 2008) 303. 
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It is interesting to note in the decision of P.A.O case the issue of non-
discrimination was not conversed before the court. Given that the Anti-Counterfeit Act 
would mostly implicate access to generic medicine in the context of HIV/AIDS, one 
would have expected the petitioners to allege a violation of the provision of non-
discrimination as contained in the Kenyan Constitution.88 More importantly, the 
petitioners in this case are women living with HIV, which further reinforces the need to 
be sensitive to their situation.  It is a known fact that in Africa HIV/AIDS bears a 
woman’s face. The recent UNAIDS figure indicates that about 60 per cent of those living 
with HIV in Africa are women and that young women are three to four times more 
vulnerable to HIV that their male counterparts.89 In addition studies have shown that 
due to their anatomy and other social cultural factors, women are more susceptible to 
HIV infection that their male counterparts. This situation necessitates a gender equality-
based approach to realising the right to health.  Aside from the historical disadvantage 
of women in many parts of the world, the HIV/AIDS pandemic has further exacerbated 
the inequality women face in many African societies.  
The principles of equality and non-discrimination are well recognised under 
international human rights law. These include article 2 of both the ICESCR and ICCPR 
and articles 2 and 12 of CEDAW.90 In its General Comment 20,91 the CESCR explained 
that the enjoyment of socio-economic rights guaranteed in the ICESCR must be without 
discrimination. In particular the CESCR notes that marginalised and vulnerable groups 
such as women, children, adolescents and people living with HIV must be given special 
attention in the enjoyment of socio-economic rights. In other words, any measure or 
steps taken by a state to realise socio-economic rights (particularly the right to health), 
must necessarily take into cognisance the situation and lived experiences of these 
groups. 
In its earlier General Comment 14, the CESCR has noted that non-discrimination 
constitutes a minimum core of the enjoyment of the right to health which is not subject 
to progressive realisation.92In the same vein, the CEDAW Committee in its General 
Comment 2493 on women and health has explained that failure or reluctance on the part 
of the states to provide health care services specifically needed by women will 
constitute an act of discrimination contrary to the provision of the convention. In one of 
its concluding observations to the government of Kenya, the CEDAW committee has 
expressed grave concern that women and girls are particularly susceptible to HIV 
infection owing to gender specific norms.94 The Committee further notes that the 
persistence of unequal power relations between women and men and inferior status of 
women and girls, may hamper their ability to negotiate for safe sex practices which may 
                                                 
88 Article 27 of the Kenyan Constitution 2010.  
89 UNAIDS above note 12.   
90 CEDAW above note 25.  
91 General Comment No. 20 of Committee on ESCR on Non-Discrimination in Economic, Social and 
Cultural Rights (article 2, para 2) E/C.12/GC/20. 
92 ICESCR General Comment 14 above note 28. 
93 General Recommendation No 24 of CEDAW on Women and Health UN GAOR, 1999,Doc A/54/38 Rev 1. 
94 CEDAW Concluding Observations: Kenya 2011, (CEDAW/C/KEN/CO/7) para 39.  
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increase their vulnerability for infection.95The Committee therefore urges the Kenyan 
government to adopt a gender sensitive approach in its HIV and AIDS prevention and 
treatment programme.  
It should be noted that, the African Commission in Legal Resources Centre v 
Zambia,96 has explained that the principles of equality and non-discrimination in 
articles 2 and 3 of the African Charter are very crucial and fundamental for the 
enjoyment of all other rights guaranteed in the African Charter. These statements attest 
to the fact that States cannot in anyway in the provision of health care services adopt a 
discriminatory approach, whether directly or indirectly .As shown in P.A.O case the fact 
that the Anti-Counterfeit Act may jeopardise access to life-saving medication for people 
living with HIV, maybe urged to constitute indirect discrimination by Kenya 
government against people living with HIV (particularly women living with HIV). 
One other missing link in P.A.O is that there is little reference by the court to the 
jurisprudence of the African Commission in order to elucidate state obligation regarding 
the right to health. Throughout the judgement the court was willing to cite 
jurisprudence of the UN Human Rights system and did not make any reference to the 
jurisprudence of the African Commission. In recent times the African Commission has 
developed important jurisprudence and resolutions with regards to the right to health 
in general and access to medicine in particular. The decisions of the African Commission 
in both SERAC97case and Purohit 98case, both clarify the nature of states obligations with 
regard to the right to health under the African Charter. More importantly, the resolution 
of the African Commission on access to medicine 99and declaration on HIV and human 
rights100 require African governments to adopt a rights-based approach to HIV and AIDS 
particularly access to medicine for those in need. The African Commission explained in 
it resolution what measure African government must take in order to realise access to 
life-saving saving medication for their citizens. Given that Kenya has ratified the African 
Charter, one would have expected the court to be also guided by the decisions and 
resolutions of the African Commission. Therefore, it may be concluded that failure to 
cite jurisprudence of the African Commission was a missed opportunity. 101 
 
                                                 
95 Ibid. 
96 Legal Resource Foundation v Zambia (2001) AHRLP 84 (ACHPR 2001) para 63. 
97Social and Economic Rights Action Centre (SERAC) and Another v Nigeria. Communication No. 155/96, 
(2001) AHRLR 60 (ACHPR 2001). 
98 Purohit v The Gambia above note 35.   
99 African Commission on Human and Peoples’ Rights, ACHPR/Res.141 (XXXXIIII)08: Resolution on 
Access to Health and needed Medicines in Africa. 
100 Resolution on the HIV/AIDS Pandemic –Threat against Human Rights and Humanity adopted at the 
29th Ordinary Session of the African Commission held in Tripoli, Libya ACHPR Res.53/(XXIX)01.  
101 According to article 2 of the Kenya Constitution, the Constitution is the “supreme law of the Republic . . 
.” and the “general rules of international law shall form part of the law of Kenya.” As such, it is our 
argument that the court should have referred to the jurisprudence of the African Commission in its 
judgement as part of international law. 
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6 CONCLUSION 
The decision P.A.O is no doubt a significant development with regard to ascertaining 
state obligation as regard access to medicine. This is one of the few cases in Africa 
where a court has been called upon to determine the nature of the state’s obligation 
with regard to intellectual property rights and the right to health. This decision 
attempted to clarify the duty of a state with regard to ensuring lifesaving medication for 
its citizens and protecting patent rights enjoyed by pharmaceutical companies. The 
judge in this case adopted a progressive;  albeit rights-based approach in balancing 
state obligation with regard to human rights and intellectual property rights.  The 
reasoning of the court in this case is a significant victory for people living with HIV and 
others who are in need of life- saving medication in Kenya and Africa as a whole.  
The fact that the court found the Kenyan government in violation of the rights to 
life, dignity and health of its citizens due to the enactment of the Anti-Counterfeit Act 
emphasises the threefold obligation of states to respect, protect and fulfil all human 
rights particularly the right to health. While the case is no doubt a positive development 
in advancing the right to health, the fact that the court failed to make a specific order as 
to when the government should amend the offending provisions of the Anti-Counterfeit 
Act, consider the jurisprudence of the African Commission and the principle of non-
discrimination raised by the case can be regarded as some of its shortcomings.  
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